-
Mashup Score: 3ClinicalTrials.gov - 13 hour(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant #Pancreatic ductal adenocarcinoma. #pancsm #oncology https://t.co/OAmVjSGz32
-
-
Mashup Score: 4
David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care @CedarsSinai #mmsm #oncology https://t.co/TwbIqSe8VI
-
-
Mashup Score: 2
Zorifertinib has received NMPA approval in the first line for EGFR-mutant advanced or metastatic non–small cell lung cancer displaying CNS metastases.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases #lcsm #oncology https://t.co/yiMGtawItp
-
-
Mashup Score: 0FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL - 17 hour(s) ago
The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL @US_FDA #leusm #oncology https://t.co/vSsR88Ohe4
-
-
Mashup Score: 5
Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers @cmpabon @SylvesterCancer #Oncology #MedEd https://t.co/DF6byme2jD
-
-
Mashup Score: 8Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer - 19 hour(s) ago
Parth A. Desai, MBBS, MD, was first author on a study that detailed significant findings in small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
@FoxChaseCancer Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer #sclc #oncology https://t.co/0wDDFPRx77
-
-
Mashup Score: 0Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients - 20 hour(s) ago
Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients @DrMaurieMarkman @cityofhope #oncology https://t.co/42bUojW5lA
-
-
Mashup Score: 0
The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elraglusib Earns @US_FDA Rare Pediatric Disease Designation for Ewing Sarcoma #oncology #scmsm https://t.co/yUTbOF5NDD
-
-
Mashup Score: 1Revumenib Meets Cr/CRh End Point in NPM1+ R/R AML - 23 hour(s) ago
Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Revumenib Meets Cr/CRh End Point in NPM1+ R/R AML @MSKCancerCenter #leusm #oncology https://t.co/ISDyO0X5my
-
Pan-KRAS inhibition is also an attractive MOA. We're excited at @ClevelandClinic to be part of this phase 1 clinical trial studying PF-07934040 in #PancreaticCancer and other solid tumors. https://t.co/4M7MeLo4ci https://t.co/Li6US1MJNa